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Abstract 
In this study 22 samples of urine sediments were obtained from patients with Urinary Bladder Carcinoma, DNA 
base technique and LOH detection was investigated in three genes P53, Rb1 and H-ras. The result are shown 
that LOH was present in most cases and for all genes where LOH in P53 represents (31.8%) and for Rb1 
(45.4%) and for H-ras gene (27.2%).In some cases, more than one gene locus mutations were found. 
 
Introduction: 
Bladder cancer is the second most common malignancy affecting the urinary system. Approximately 90% of 
urothelial tumours are urothelial cancers (UCs). The remaining tumours are squamous cell cancers or 
adenocarcinomas. Small-cell carcinomas account for less than 1%. The spectrum of bladder cancer includes 
non–muscle-invasive, muscle-invasive, and metastatic disease, each with its own specific typical behaviour, 
prognosis, and treatment (Vrooman O.& Witjes j.2008). 
Bladder cancer is one of the most common cancers in human. Almost there are two major types. Approximately 
70% of bladder cancer patients present with non-muscle invasive (NMI) tumors, which recur frequently and are 
usually not fatal but make bladder cancer one of the most expensive cancers to treat . The remaining 30% of 
patients present with muscle-invasive (MI) tumors.( Jin X.et al 2014 ; Dancika G. et al 2013) 
DNA-Based techniques reflect more strongly invasiveness and prognosis of the cancer and these techniques may 
be used as a good addunctive tests for evaluation of the bladder cancer.( Zachary L.et al 2013; Wang P.et al 
2014) . 
 LOH at the region of a known tumor suppressor gene is considered indicative of a mutation in the remaining 
copy of the gene, resulting in the loss of the tumor suppressing function of the gene product. Several studies 
reported frequent alterations of chromosome 9, occurring early tumorigenesis, but also present at all stages and 
grades (Ploussard G .et al 2010).            
The detection of Loss of Heterozygosity (LOH)  for some genes associated with tumors was highly investigated 
and LOH was considered as the most frequent mutation of some genes such as P53, Rb1 &H-ras , which arise 
from relatively large deletions particularly in the exons(Innis M. et al 1990 ). 
 Loss of heterozygosity (LOH) has been described as a distinct and frequent type of molecular alterations. LOH 
at the region of a known tumor suppressor gene is considered indicative of a mutation in the remaining copy of 
the gene, resulting in the loss of the tumor suppressing function of the gene product. 
( Burger M..et al 2006 , Berger A.et al 2002).  
On the other hand P53, Rb1 and H-ras genes are tumor suppressor genes and are considered very essential in 
control and regulation of other genes particularly oncogene, RAS mutations common in non-muscle invasive 
(NMI) tumors and P53/RB1 impairment common in muscle-invasive(MI )tumors (Dancika G. et al 2013).  
The aim of this study is to detect of LOH in patients with Urinary Bladder Cancer by using three genetic markers 
for P53 , Rb1 & H-ras. 
 
Material and Methods 
Patients: urine sediments are obtained from 24 patients with urinary bladder carcinoma. 
DNA extraction: DNA extraction from leukocyte fractions, the urine sediments was done by Sacace DNA 
extraction kit, using manufacturer's protocol.  
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Primers:  DNA amplified with three primers. 
5 – GAT GCT GTC CGC GGA CGA TAT -3 p53 (F) 
5 – CGT GCA AGT CAC AGA CTT GGC -3 p53(R) 
5- TT CAA TGA AGA ACA AAT GG -3 Rb1(F) 
5- GCA ATT GCA CAA TCC AAG TT – 3 Rb1(R) 
5-GAC-GGA-ATA-TAA-GGC-TTG-TTG-3 H-ras(F) 
5- TGG-ATG-GTC-AGC-GCA-CTC-TT-3 H-ras(R) 
 
Samples were amplified in the manufacturer’s reaction buffer containing 20 pmol of each primer, 0.2 mM of 
each dNTP, 2 mM MgCl2, and 2 U Taq DNA polymerase(promega) Amplification was carried out for p53(94◦ 
C for 2 minute), of 40 s at 95◦ C , 35s at 58 ◦C  & 35 C at 72 C  at 40 cycle minutes. Rb1 1 minute at 94◦ C,  1 
minute at 50◦ C  and 1 minute at 72◦ C for 30 cycles.H-ras 94C◦ for 5 min, 94C◦ for 15 Second, at 65 C◦ for 30 
Second at 35 cycles. 
Restriction fragment length polymorphism (RFLP) analysis.  
After amplification, 25 ul. of PCR products was digested with 2 to 20 units of the appropriate restriction 
enzyme(Bst UI , Xba1 & Msp1) for p53 ,Rb1 &H-ras respectively over night.. Each product was run on an 
agarose , which was stained with ethidium bromide and photographed under ultraviolet light. Loss of 
heterozygosity(LOH) was defined as a visible change of 1 allele in the tumor DNA compared with normal DNA. 
When normal DNA did not show 2 different alleles (that is, homozygous), the case was considered 
uninformative. 
 
Discussion: 
Loss of Heterozygosity (LOH): 
LOH studied by using DNA extraction from urine sediment for patients with urinary bladder carcinoma & the 
main markers used in this study is P53 , Rb1 and H-Ras genes. 
Identification of DNA mutations in urine sediments has been proposed as a noninvasive and early indicator of 
urinary tract cancer. 
 
Figure(1) P53 gene , Bst UI  digestion PCR product of the urine sediement DNA , L= DNA size marker ; 
C= Control; 1,2,3,4,8, 9,10,11 =heterozygous patients 5,6,7= homozygous who are uniformative for LOH 
Total of (22) Patients subjected for this study who have Urinary Bladder carcinoma, it was shown that 7(31.8%) 
patients was positive for LOH as shown in Figure (1). 
The result have suggested that detection of LOH of P53 gene by PCR-RFLP may be a good tool for evaluation 
of bladder cancer and according to the data mentioned by (Borkowska  et al , 2007). 
In healthy controls the lymphocyte and urine DNA displayed the same electrophoretic patterns, which indicated 
absence of microsatellite alterations. (Sourninos G.et al 2001) 
It is considered the present of one band or two band are uninformative and homozygous whereas the presence of 
three band are informative and heterozygous also are natural in the genome. 
Many studies have confirmed that P53 has a role in Urinary Bladder Carcinoma when exposed to mutation 
(Berggren et al, 2001).And also in colon cancer & prostate cancer (Spajic B. et al.2005). 
 
These studies revealed that P53 gene mutation are usually seen to occur as late events in Bladder tumorigenesis 
& also it was showed that LOH at P53 loci is higher significant and being associated with tumor grade& stages 
(Telu K.et al 2013). 
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LOH studies suggest that deletions of the p53 gene occur frequently during the development and progression of 
urotherial carcinoma of the urinary bladder. ( Cheng L.et al 2004) 
The result of this study are correlated with that obtained by Hiroshi M. et al 1996,who found 38% showed LOH  
at one or more loci. 
Although P53 gene was proved its role in Bladder tumorigenesis but in the present study have showed that only 
(31.8%) of patients give positive result for LOH as a result of P53 mutation &the result are normal for this gene 
this result suggest that P53 mutation may occur at the last grade &stages not that early stages as mentioned by 
(Borkowska  et al , 2007). 
 
Figure(2): Rb1 gene , Xba1  digestion PCR product of the urine DNA, L= DNA size marker C= Control 
2,5,6,7,8,11=heterozygous patients 1,3,4,9,10 = homozygous who are uniformative for LOH 
About 10 of 22  patients(45.4%)  uninformative cases showed LOH at the Rb1.Rb1 is as P53 is tumor suppressor 
gene which involved in pathogenesis & progression of Urinary Bladder carcinoma. LOH of Rb1 gene has 
frequently be seen in Retinoblastoma, Bladder, Prostate, Breast & Lung carcinoma. 
The result of this study as correlated with that (Acikbas I.et al 2002) that over 40% of Bladder cancer have 
positive Rb1 LOH and also with that (Traczyk M. et al 2011) who found that 34% of Urinary bladder carcinoma 
were positive for Rb1 LOH and this frequency is lower (12.5%)than reported in some researchers (Gallucci M.et 
al 2005).  
According to positive data obtained in this study, It was shown that Rb1 is mostly seen in cases negative to P53 
,except three cases which have positive to P53 this suggests  that Rb1 LOH occur mostly in early stages of 
cancer and mainly in tissues with low grade as mentioned by (Traczyk M. et al 2011; Wada T.et al 2000  
).Besides, the present study is correlated with that stated by (Philips S. 1994), who observed that most cases of 
Rb1 LOH is carried out in the early stage of tumorigensis in the bladder. Some studies revealed the presence of 
co existent abnormalities of multiple tumor suppressor gene and also suggested cooperative roles for both P53 
&Rb1 genes, Here it was observed two loci for the cases that positive simultaneously for Rb1 LOH & P53 LOH. 
This result suggests that the cases reach high grades & stages this result identical to that obtained by (Miyamoto 
H. et al 1996). 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.4, No.19, 2014 
 
157 
 
 
Figure (3) H-ras gene ,MspI digestion PCR product of urine sediment DNA ,L=DNA size marker; C= 
control 1,2,3,4,5,6,9,10,11= heterozygous patients  7, 8 =homozygous patients who are uniformative for 
LOH 
In addition to P53, Rb1 LOH, H-ras LOH is also invistigated , it was seen that only 6 (27.2%)patients gave 
positive  for H-ras LOH ,whereas the others are normal for this gene (figure3). 
H-ras gene is Known has a role in many cancers such as lung, bladder, breast& skin and this gene is considered 
as pro- Oncogene ( Kratz C.et al 2007). 
LOH of H-ras in human tumor may indicate that this gene has a tumor suppressor role, since normal H-ras can 
suppress the malignant phenotype of transformed cell lines, acting as a tumor suppressor gene (Gorringe K. et al 
2009).  
The present study also showed that H-ras LOH was simultaneously associated with P53 &Rb1 in some cases and 
it is known that there is no correlation between tumor grade and stages with H-ras mutation. But Ras mutations 
common in NMI tumors and P53/RB1 impairment common in MI tumors (Dancika G. et al 2013). 
The Ras genes are the most common mutations found in Bladder cancer and up to 13% of all bladder tumours 
harbour a mutation in H-ras, K-ras or N-ras. There is limited data available regarding these oncogenic mutations 
in BC of patients ˂20 years. ( Beukers W. et al 2013) 
But H-ras gene was found to associate with other cancer cells particullay in Prostate, neck & head and so (Kiaris 
H.et al 1994). 
Patients who exhibited microsatellite alterations (LOH) in urine specimens exclusively had early, moderate or 
late stages and grade I, II or III disease. 
Briefly prospective analysis of bladder tumors involving each of these genetic loci implicate P53 inactivation as 
a late events in progression that is associated with the transition of tumor from a low grade to a high grade 
lesion(Sidransky D.et al 1991, Fujimoto K.et al 1992 , Sarkis A.et al 1993). 
Loss of expression of Rb1 gene product is associated with the invasive phenotype, and both the P53 and Rb1 
genes have been proposed as indpendent prognostic indicators of progression in Bladder cancer 
 ( Cardo C.et al 1992) 
Some studies have shown an association of the H-ras mutations with low-grade, noninvasive superficial 
papillary urothelial tumors, while others have suggested that the mutations play a role in bladder tumor invasion 
(Mo L. et al 2007); and also Jebar A.et al 2005 found no correlation between H-ras mutations and tumor 
progression . 
Finely the detection of loss of heterozygosity in cytological urine specimens may be prognostic indicator of early 
detection of bladder cancer. 
Many studies have examined only H-ras and have reported a wide range of mutation frequencies (0- 70%) that 
may reflect true differences in the tumors examined or technical differences between assays. Currently, there is 
agreement from several studies that the frequency for H-ras is in the range of 10-20 % ( Pandith A. et al 2010). 
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